Toward the integration of biosimilars into pediatric rheumatology: adalimumab ABP 501 experience of PeRA research group

Expert Opin Biol Ther. 2022 Feb;22(2):197-202. doi: 10.1080/14712598.2021.2002296. Epub 2021 Nov 16.

Abstract

Objectives: To review the real-life data, to provide an input to the literature concerning treatment of juvenile idiopathic arthritis (JIA) with adalimumab (ADL) biosimilar.

Method: This multi-centric retrospective study was conducted among children with JIA, followed up for at least 24-weeks from the initiation of ADL biosimilar (ABP 501) treatment. Adverse events and alterations in disease activity scores were figured out.

Results: The median age of the group was 15.5 (5-18) years. JIA categories were oligoarticular (n =12), enthesitis-related (ERA) (n=24), psoriatic (PsA) (n=6), and polyarticular (n=4). Uveitis was detected at the initiation of the disease (n=3), during the disease course (n=5), or before the diagnosis (n=1). The first-line treatment preferences were ADL biosimilar (n=37) and etanercept (n=9). On the 6th month of ABP 501, 40 (86.9%) patients had achieved complete remission. Six patients (1 PsA, 1 polyarticular JIA, and 4 ERA) had ongoing active arthritis. Furthermore, all except one of the patients had remission of ophthalmologic findings. No life-threatening adverse events were observed.

Conclusions: ABP 501 has a gradual increase in prescription in pediatric rheumatology. Real-life data of the cohort announce that ADL biosimilar is a suitable and effective treatment option for patients with JIA in case of indication.

Keywords: ABP-501; Adalimumab; amgevita; biosimilar; juvenile idiopathic arthritis.

Publication types

  • Multicenter Study

MeSH terms

  • Adalimumab / adverse effects
  • Adolescent
  • Antirheumatic Agents* / adverse effects
  • Arthritis, Juvenile* / diagnosis
  • Arthritis, Juvenile* / drug therapy
  • Biosimilar Pharmaceuticals* / adverse effects
  • Child
  • Humans
  • Retrospective Studies
  • Rheumatology*
  • Treatment Outcome

Substances

  • ABP 501
  • Antirheumatic Agents
  • Biosimilar Pharmaceuticals
  • Adalimumab